Sarepta Therapeutics, Inc. (SRPT): Price and Financial Metrics

Sarepta Therapeutics, Inc. (SRPT): $79.69

-0.55 (-0.69%)

POWR Rating

Component Grades













Add SRPT to Watchlist
Sign Up

Industry: Biotech


of 508

in industry


  • Value is the dimension where SRPT ranks best; there it ranks ahead of 72.95% of US stocks.
  • SRPT's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • SRPT's current lowest rank is in the Momentum metric (where it is better than 9.55% of US stocks).

SRPT Stock Summary

  • Of note is the ratio of Sarepta Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 12.93% of US stocks have a lower such ratio.
  • With a price/sales ratio of 10.6, Sarepta Therapeutics Inc has a higher such ratio than 82.8% of stocks in our set.
  • With a year-over-year growth in debt of 51.1%, Sarepta Therapeutics Inc's debt growth rate surpasses 86.69% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Sarepta Therapeutics Inc, a group of peers worth examining would be CTMX, IDYA, JNCE, MEIP, and ASMB.
  • Visit SRPT's SEC page to see the company's official filings. To visit the company's web site, go to

SRPT Valuation Summary

  • In comparison to the median Healthcare stock, SRPT's price/sales ratio is 8.37% lower, now standing at 10.4.
  • SRPT's price/earnings ratio has moved up 3.9 over the prior 243 months.
  • SRPT's price/sales ratio has moved down 648 over the prior 243 months.

Below are key valuation metrics over time for SRPT.

Stock Date P/S P/B P/E EV/EBIT
SRPT 2021-08-31 10.4 12.9 -9.8 -9.0
SRPT 2021-08-30 10.1 12.5 -9.5 -8.7
SRPT 2021-08-27 10.5 13.0 -9.9 -9.1
SRPT 2021-08-26 10.4 12.9 -9.9 -9.0
SRPT 2021-08-25 10.6 13.2 -10.1 -9.2
SRPT 2021-08-24 10.3 12.7 -9.7 -8.9

SRPT Growth Metrics

  • The 5 year net income to common stockholders growth rate now stands at -198.11%.
  • Its 4 year net cashflow from operations growth rate is now at 290.38%.
  • Its 3 year revenue growth rate is now at 25713.33%.
SRPT's revenue has moved up $598,829,000 over the prior 67 months.

The table below shows SRPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 600.082 -702.238 -634.471
2021-03-31 573.356 -700.695 -703.886
2020-12-31 540.099 107.466 -554.128
2020-09-30 495.074 118.206 -600.514
2020-06-30 450.191 288.961 -530.341
2020-03-31 407.496 317.56 -655.924

SRPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRPT has a Quality Grade of C, ranking ahead of 59.3% of graded US stocks.
  • SRPT's asset turnover comes in at 0.213 -- ranking 193rd of 680 Pharmaceutical Products stocks.
  • LIFE, GLYC, and CBIO are the stocks whose asset turnover ratios are most correlated with SRPT.

The table below shows SRPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.213 0.868 -0.332
2021-03-31 0.201 0.872 -0.375
2020-12-31 0.186 0.883 -0.313
2020-09-30 0.190 0.886 -0.376
2020-06-30 0.192 0.879 -0.357
2020-03-31 0.198 0.860 -0.473

SRPT Price Target

For more insight on analysts targets of SRPT, see our SRPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $118.39 Average Broker Recommendation 1.5 (Moderate Buy)

SRPT Stock Price Chart Interactive Chart >

Price chart for SRPT

SRPT Price/Volume Stats

Current price $79.69 52-week high $181.83
Prev. close $80.24 52-week low $65.30
Day low $79.32 Volume 705,000
Day high $80.85 Avg. volume 1,356,583
50-day MA $83.97 Dividend yield N/A
200-day MA $80.42 Market Cap 6.36B

Sarepta Therapeutics, Inc. (SRPT) Company Bio

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.

SRPT Latest News Stream

Event/Time News Detail
Loading, please wait...

SRPT Latest Social Stream

Loading social stream, please wait...

View Full SRPT Social Stream

Latest SRPT News From Around the Web

Below are the latest news stories about Sarepta Therapeutics Inc that investors may wish to consider to help them evaluate SRPT as an investment opportunity.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) Has Reached A Distance Of 18.62% From Its Low, So Is It Poised For More Gains?

In last trading session, Sarepta Therapeutics Inc. (NASDAQ:SRPT) saw 0.69 million shares changing hands with its beta currently measuring 1.30. Companys recent per share price level of $80.24 trading at -$0.68 or -0.84% at ring of the bell on the day assigns it a market valuation of $6.32B. That closing price of SRPTs stock is Sarepta Therapeutics Inc. (NASDAQ:SRPT) Has Reached A Distance Of 18.62% From Its Low, So Is It Poised For More Gains? Read More »

Marketing Sentinel | October 23, 2021

Aptinyx Appoints Gilmore ONeill, M.B., M.M.Sc., to Board of Directors

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore ONeill, M.B., M.M.Sc., to the companys board of directors. Dr. ONeill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. Gilmore brings an exceptional background of experience and leadership

Business Wire | October 20, 2021

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock Holdings Increased by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 2,400,000 shares of the biotechnology companys stock after acquiring an additional 250,000 shares during the quarter. Sarepta Therapeutics comprises approximately 3.2% of Avoro []

Transcript Daily | October 20, 2021

Is This Beaten Down Biotech a Bad News Buy?

It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?

Yahoo | October 20, 2021

11 Best Genomic Stocks to Buy Now

In this article, we will take a look at the 11 best genomic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Genomic Stocks to Buy Now. Genomics is a branch of biology that studies the structure, function, evolution, mapping, and editing of genomes, […]

Yahoo | October 19, 2021

Read More 'SRPT' Stories Here

SRPT Price Returns

1-mo -12.01%
3-mo 15.39%
6-mo 11.60%
1-year -42.51%
3-year -34.88%
5-year 95.27%
YTD -53.26%
2020 32.12%
2019 18.24%
2018 96.14%
2017 102.84%
2016 -28.90%

Continue Researching SRPT

Want to see what other sources are saying about Sarepta Therapeutics Inc's financials and stock price? Try the links below:

Sarepta Therapeutics Inc (SRPT) Stock Price | Nasdaq
Sarepta Therapeutics Inc (SRPT) Stock Quote, History and News - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8855 seconds.